| Literature DB >> 32787768 |
Constantin Bodolea1,2, Elisabeta I Hiriscau2,3, Elena-Cristina Buzdugan4,5, Alin I Grosu4,5, Laurențiu Stoicescu4,5, Ștefan Vesa6, Omar Cauli7.
Abstract
BACKGROUND: Frailty syndrome is characterized by multisystem dysregulation frequently found in older individuals or even in younger patients with chronic disabling diseases such as cardiovascular diseases.Entities:
Keywords: Cardiovascular diseases; frailty; malnutrition; neutrophil-to-lymphocyte ratio; peripheral blood count; platelet-tolymphocytezzm321990ratio; red blood cell distribution width; red cell distribution width-to-platelet ratio; white blood count
Year: 2020 PMID: 32787768 PMCID: PMC8226153 DOI: 10.2174/1871530320666200813135905
Source DB: PubMed Journal: Endocr Metab Immune Disord Drug Targets ISSN: 1871-5303 Impact factor: 2.895
Fig. (2)Comparisons of ROC curves for lymphocytes, hemoglobin and platelets. Hb, Hemoglobin; LY, Lymphocytes, PLT, platelets. (A higher resolution / colour version of this figure is available in the electronic copy of the article).
Fig. (3)Comparisons of ROC curves for RDW-CV, RDW-SD, RPR and NLR. RDW, red cell distribution width; RPR, red cell distribution-to-platelets ratio, NLR, neutrophils-to-lymphocytes ratio. (A higher resolution / colour version of this figure is available in the electronic copy of the article).
Distribution in quartiles of ratios variables (NRL, PLR, RPR).
|
|
|
|
|
|
|---|---|---|---|---|
| NLR | 0-2.1 | 2.1-3.1 | 3.1-4.4 | > 4.4 |
| PLR | 0-100.4 | 100.4- 136.9 | 136.9- 194.3 | > 194.3 |
| RPR | 0-0.0485 | 0.0485- 0.0594 | 0.0594- 0.0747 | > 0.0747 |
Baseline characteristics of the sample including in the analysis. Quantitative variables are expressed by mean (M) and standard deviation (SD), and qualitative variables as a percentage.
|
| |
|---|---|
| Age (years) | M = 65.07 SD = 12.9 |
| Gender | Males = 78 (43.6%) |
| Origin environment | Rural = 92 (51.4%) |
| Marital/Civil status | Married = 115 (64.2%) |
| Level of education | Elementary education = 75 (41.9%) |
| BMI (kg/m2) | 0 (BMI<19) = 0.6% |
| Nutritional status | 0 (normal nutritional status) = 60.9% |
| Polypharmacy expressed as a number of daily intake medications (considered positive | Polypharmacy = 132 (73.7%) |
| Number of frail (fulfilled ≥3 Fried criteria) and non-frail (fulfilled 0, 1 or 2 Fried criteria) individuals | Frail = 79 (44.1%) |
| (Documented) Ischemic heart disease | 111 (62%) |
| Percutaneous transluminal coronary angioplasty (PTCA) | 5 (2.8%) |
| Arterial hypertension | 143 (79.9%) |
| Cardiac valvulophaties | 111 (62%) |
| Arrhythmias | 93 (52%) |
| Conduction disorders | 13 (7.3%) |
| Pacemaker | 10 (5.6%) |
| Congestive heart failure | 71 (39.6%) |
| Cerebrovascular/Neurological diseases | 31 (18.3%) |
| Diabetes | 52 (29.1%) |
| Hypercholesterolemia | 66 (36.9%) |
| Hypertriglyceridemia | 37 (20.7%) |
| Digestive disorders | 73 (40.8%) |
| Pulmonary disease | 68 (37%) |
| Kidney disease | 85 (47.5%) |
| Neoplasia | 32 (17.9%) |
| Leukocytes (109/L) | 8.1 |
| Neutrophils (109/L) | 5.4 |
| Lymphocytes (109/L) | 1.8 |
| Monocytes (109/L) | 0.7 |
| Eosinophils (109/L) | 0.2 |
| Basophils (109/L) | 0.02 |
| Platelets (109/L) | 241.5 |
| RDW-CV (%) | 14.5 |
| RDW-SD (fl) | 47.2 |
| Neutrophils/Lymphocytes ratio | 3.5 |
| Platelets/Lymphocytes ratio | 158 |
| RDW-CV/platelets ratio | 0.07 |
RDW, red blood cell distribution width; PLT, platelets; NLR, neutrophils-to-lymphocytes ratio; PLR, platelets-to-lymphocytes ratio, RPR, red blood cell distribution width-to-platelets ratio, BMI, Body Mass Index.
Comparison of non-frail and frail groups regarding cardiac diseases and comorbidities.
|
|
|
| |
|---|---|---|---|
| (Documented) Ischemic cardiac disease | 52 | 59 | |
| Percutaneous Transluminal Coronary Angioplasty (PTCA) | 2 | 3 | 0.65 |
| Arterial hypertension | 76 | 67 | 0.19 |
| Cardiac valvulopathies | 51 | 60 | |
| Arrhythmias | 43 | 50 | |
| Conduction disorders | 8 | 5 | 0.76 |
| Pacemaker | 5 | 5 | 0.75 |
| Congestive heart failure | 36 | 51 | |
| Cerebrovascular/Neurological diseases | 10 | 21 | |
| Diabetes | 23 | 29 | |
| Hypercholesterolemia | 46 | 20 | |
| Hypertriglyceridemia | 21 | 16 | 1.000 |
| Digestive disorders | 43 | 30 | 0.542 |
| Pulmonary disease | 29 | 39 | |
| Kidney disease | 45 | 40 | 0.547 |
| Neoplasia | 15 | 17 | 0.326 |
Statistically significant P values (P<0.05) are indicated in bold.
Comparisons of non-frail and frail group (Mann-Whitney U test). Quantitative variables are expressed by mean (M) and standard deviation (SD), and qualitative variables as a percentage.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Age (years) | Non-frail | 100 | 61.23 | 11.673 | |
| Education (years) | Non-frail | 100 | 11.08 | 3.32 | |
| Marital status (married) | Non-frail | 76/100 (76%) | - | - | |
| Leukocytes | Non-frail | 100 | 7.953 | 2.329 | 0.58 |
| Neutrophils | Non-frail | 100 | 5.254 | 2.228 | 0.26 |
| Lymphocytes | Non-frail | 100 | 1.945 | 0.759 | |
| Monocytes | Non-frail | 100 | 0.665 | 0.225 | 0.97 |
| Eosinophils | Non-frail | 100 | 0.154 | 0.119 | 0.66 |
| Basophils | Non-frail | 100 | 0.028 | 0.015 | 0.88 |
| Haemoglobin | Non-frail | 100 | 13.938 | 1.803 | |
| RDW-CV | Non-frail | 100 | 14.013 | 1.745 | |
| RDW-SD | Non-frail | 100 | 45.658 | 6.245 | |
| PLT | Non-frail | 100 | 254.00 | 70.608 | |
| NLR | Non-frail | 100 | 3.2 | 2.17 | |
| PLR | Non-frail | 100 | 153.203 | 84.680 | 0.21 |
| RPR | Non-frail | 100 | 0.059 | 0.021 | |
| Polypharmacy | Non-frail | 64/100 (64%) | - | - | |
| Charlson Comorbidity Index | Non-frail | 100 | 4.93 | 2.306 | |
| Nutritional status | Non-frail | 100 | 0.27 | 0.489 | |
| BMI | Non-frail | 100 | 2.87 | 0.418 | 0.053 |
Statistically significant P values (P<0.05) are indicated in bold.
Results of predictors including in the model.
|
|
|
|
|
|
|---|---|---|---|---|
| Nutritional status | 1,260 | 3,526 | 1,926-6,454 | |
| Educational level | -0,145 | 0,865 | 0,783-0,956 | |
| Haemoglobin | -0,194 | 0,823 | 0,690-0,983 | |
| PLT | -0,008 | 0,992 | 0,987-0,997 | |
| NLR | 0,147 | 0.98 | 1,158 | 0,973-1,379 |
| Congestive heart failure | -0,804 | 0,447 | 0,220-0,911 | |
| Cardiac valvulopathies | -1,053 | 0,349 | 0,168–0,723 | |
| Pulmonary disease | -1,028 | 0,358 | 0,175–0,732 | |
| Cerebrovascular diseases | -2,269 | 0,103 | 0,023-0,460 | |
| Hypercholesterolemia | 0,746 | 2,109 | 1,045–4,256 | |
| Diabetes | -0,945 | 0,389 | 0,170–0,886 | |
| Polypharmacy | -0,867 | 0.70 | 0,420 | 0,164-1,074 |
| CCI | 0,064 | 0.40 | 1,066 | 0,917-1,240 |
Statistically significant P values (P<0.05) are indicated in bold.